Metastasiertes kastrationsresistentes Prostatakarzinom: Neues zu Cabazitaxel unter Berücksichtigung der aktuellen Datenlage

J. E. Gschwend; P. Albers; M. Bögemann; P. Goebell; A. Heidenreich; J. Klier; F. König; S. Machtens; K. Pantel; C. Thomas

doi:10.1007/s00120-017-0533-y

Metastasiertes kastrationsresistentes Prostatakarzinom: Neues zu Cabazitaxel unter Berücksichtigung der aktuellen Datenlage

Translated title of the contribution: Metastatic castration-resistant prostate cancer: Use of cabazitaxel taking into consideration current data

J. E. Gschwend, P. Albers, M. Bögemann, P. Goebell, A. Heidenreich, J. Klier, F. König, S. Machtens, K. Pantel, C. Thomas

Research output: Contribution to journal › Article › peer-review

Abstract

Background: At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented. Objectives: The focus is on the clinical impact of these data. Materials and methods: A group of German experts in the field of urogenital–oncologic expertise discussed the clinical impact with respect to the current data. Results: The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients with mCRPC. Conclusions: Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20 mg/m² cabazitaxel.

Translated title of the contribution	Metastatic castration-resistant prostate cancer: Use of cabazitaxel taking into consideration current data
Original language	German
Pages (from-to)	34-39
Number of pages	6
Journal	Urologe - Ausgabe A
Volume	57
Issue number	1
DOIs	https://doi.org/10.1007/s00120-017-0533-y
State	Published - 1 Jan 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00120-017-0533-y

Cite this

@article{298fd7f4a4234df29a9433a00e16bee2,

title = "Metastasiertes kastrationsresistentes Prostatakarzinom: Neues zu Cabazitaxel unter Ber{\"u}cksichtigung der aktuellen Datenlage",

abstract = "Background: At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented. Objectives: The focus is on the clinical impact of these data. Materials and methods: A group of German experts in the field of urogenital–oncologic expertise discussed the clinical impact with respect to the current data. Results: The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients with mCRPC. Conclusions: Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20 mg/m2 cabazitaxel.",

keywords = "Cabazitaxel, Docetaxel, Patient selection, Prostate cancer, metastatic castration-resistant, Therapy, endocrine",

author = "Gschwend, {J. E.} and P. Albers and M. B{\"o}gemann and P. Goebell and A. Heidenreich and J. Klier and F. K{\"o}nig and S. Machtens and K. Pantel and C. Thomas",

note = "Publisher Copyright: {\textcopyright} 2017, Springer Medizin Verlag GmbH.",

year = "2018",

month = jan,

day = "1",

doi = "10.1007/s00120-017-0533-y",

language = "Deutsch",

volume = "57",

pages = "34--39",

journal = "Urologe - Ausgabe A",

issn = "0340-2592",

publisher = "Springer Medizin",

number = "1",

}

TY - JOUR

T1 - Metastasiertes kastrationsresistentes Prostatakarzinom

T2 - Neues zu Cabazitaxel unter Berücksichtigung der aktuellen Datenlage

AU - Gschwend, J. E.

AU - Albers, P.

AU - Bögemann, M.

AU - Goebell, P.

AU - Heidenreich, A.

AU - Klier, J.

AU - König, F.

AU - Machtens, S.

AU - Pantel, K.

AU - Thomas, C.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented. Objectives: The focus is on the clinical impact of these data. Materials and methods: A group of German experts in the field of urogenital–oncologic expertise discussed the clinical impact with respect to the current data. Results: The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients with mCRPC. Conclusions: Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20 mg/m2 cabazitaxel.

AB - Background: At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented. Objectives: The focus is on the clinical impact of these data. Materials and methods: A group of German experts in the field of urogenital–oncologic expertise discussed the clinical impact with respect to the current data. Results: The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients with mCRPC. Conclusions: Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20 mg/m2 cabazitaxel.

KW - Cabazitaxel

KW - Docetaxel

KW - Patient selection

KW - Prostate cancer, metastatic castration-resistant

KW - Therapy, endocrine

UR - http://www.scopus.com/inward/record.url?scp=85032209803&partnerID=8YFLogxK

U2 - 10.1007/s00120-017-0533-y

DO - 10.1007/s00120-017-0533-y

M3 - Artikel

C2 - 29071398

AN - SCOPUS:85032209803

SN - 0340-2592

VL - 57

SP - 34

EP - 39

JO - Urologe - Ausgabe A

JF - Urologe - Ausgabe A

IS - 1

ER -

Metastasiertes kastrationsresistentes Prostatakarzinom: Neues zu Cabazitaxel unter Berücksichtigung der aktuellen Datenlage

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this